What changed between these versions
A substantive restructuring of data requirements for biosimilar licensure. v2 refines the conditions under which the Secretary can require specific clinical studies for biosimilar approval, explicitly including immunogenicity assessment in standard requirements while establishing a formal procedure for requiring pharmacodynamics or efficacy studies. It also streamlines biosimilar reviews by deleting an existing subparagraph from the Public Health Service Act.
Overview
A handful of significant changes concentrated within Section 2. · v2 refines and clarifies the data requirements for biosimilar licensure, particularly regarding clinical studies, and streamlines the review process by removing a provision.
The most significant change in v2 is the restructuring of the requirements for clinical studies in biosimilar applications. While v1 gave the Secretary discretion to require immunogenicity, pharmacodynamics, or comparative clinical efficacy studies with justification, v2 explicitly includes immunogenicity in the standard assessment and establishes a more formal procedure, including written determinations and amendment rules, for requiring pharmacodynamics or efficacy studies. Additionally, v2 streamlines biosimilar reviews by deleting an existing subparagraph from the Public Health Service Act.
Major additions
This new subclause establishes a detailed procedure for the Secretary to require clinical studies assessing pharmacodynamics or efficacy for biosimilar licensure. It mandates a written determination of necessity, specifies timelines for providing this determination (with meeting minutes or within 60 days of application), and outlines conditions under which such a determination can be amended (by agreement or with scientific justification and a meeting).
This addition formalizes and potentially limits the Secretary's discretion in requiring certain clinical studies, providing greater predictability and transparency for biosimilar applicants. It ensures that any such requirements are justified and communicated early in the development process, potentially expediting biosimilar development and approval.
Deletions
This deleted clause in v1 allowed the Secretary, in their discretion, to require assessment of immunogenicity, pharmacodynamics, or comparative clinical efficacy in clinical studies, provided a written justification was given to the applicant by the earliest filing date.
The deletion removes the broad discretionary power of the Secretary as outlined in v1 for requiring these specific assessments. While the intent to manage these requirements remains, v2 replaces this broad discretion with a more structured and conditional framework, including specific procedural requirements for justification and communication.
v2 deletes subparagraph (B) from Section 351(k)(5) of the Public Health Service Act. While the specific text of the original subparagraph (B) is not provided, its deletion, within the context of "Streamlining Biosimilar Reviews," indicates the removal of a requirement or condition related to biosimilar applications. Historically, this subparagraph has related to the "totality of the evidence" standard or specific data requirements for interchangeability.
The removal of this subparagraph aims to streamline the biosimilar review process by eliminating a specific data requirement or standard that was previously mandated. This could potentially reduce the burden on applicants and accelerate the approval of biosimilar products.
Modifications
Biosimilar applicants are now explicitly required to include immunogenicity assessment as part of their standard data submission, potentially increasing the initial data requirements but also providing clarity on expectations. The flexibility to rely on other studies for this assessment could mitigate additional burden.
Before
Required "a clinical study or studies assessing pharmacokinetics that are sufficient to demonstrate safety, purity, and potency."
After
Requires "an assessment of pharmacokinetics and immunogenicity (which may rely on, or consist of, a clinical pharmacokinetics study or studies described in item (aa) or (dd)), as appropriate."
This modification ties the requirement for general clinical studies to a more structured and justified process, as detailed in the new subclause (ii)(II). It also refines the standard for these studies to focus on demonstrating clinical equivalence to the reference product, which could influence study design and endpoints for biosimilar applicants.
Before
Required "a clinical study or studies that are sufficient to demonstrate safety, purity, and potency in 1 or more appropriate conditions of use... subject to clause (iv)."
After
Requires "a clinical study or studies, if required by the Secretary pursuant to clause (ii)(II), to support a demonstration that there is no clinically meaningful difference between the biological product and the reference product in terms of safety, purity, and potency of such product."
This change primarily serves to organize the statutory text, making room for the new detailed procedures for requiring specific clinical studies. It does not alter the substance of the original clause (ii) but sets the stage for the new procedural requirements.
Before
The existing clause (ii) heading was "Determination" and the text began "The Secretary may".
After
The clause heading is changed to "Determinations", and the existing text is re-designated as subclause (I) "In general.--The Secretary may".
Ensures that the changes related to streamlining biosimilar reviews (deletion of subparagraph (B) and redesignation of (C)) are also applied to applications submitted after the enactment date, consistent with the other amendments.
Before
Stated that amendments made by "subsection (a)" apply to applications submitted on or after the date of enactment.
After
States that amendments made by "subsections (a) and (b)" apply to applications submitted on or after the date of enactment.
Scope
Meaningful expansion or narrowing — Changes are concentrated within Section 2, which amends a specific part of the Public Health Service Act related to biosimilar licensure. — v2 represents a refinement within the same policy direction as v1, aiming to facilitate biosimilar access. However, it significantly alters the regulatory framework for clinical studies by formalizing requirements and procedures, rather than relying on broad Secretarial discretion. — The changes directly modify existing provisions of the Public Health Service Act, particularly those governing data requirements and the review process for biosimilar products. The new procedural requirements for clinical studies interact with and supersede the more general discretionary authority previously envisioned.
Impact analysis
Sponsors of biosimilar biological products
Procedural gain and increased clarity.
v2 provides a more structured and predictable regulatory pathway for biosimilar development by formalizing the conditions under which certain clinical studies (pharmacodynamics or efficacy) can be required. It also explicitly includes immunogenicity assessment as a standard requirement.
The Food and Drug Administration (FDA) (specifically the Secretary of Health and Human Services)
Procedural change, with increased accountability and transparency requirements.
The Secretary's discretion regarding clinical study requirements is now subject to more stringent procedural safeguards, including written justifications, specific timelines, and conditions for amending determinations.
Patients and healthcare providers (indirectly)
Potential benefit through increased access and affordability of biological products.
The streamlining of biosimilar reviews and the clearer regulatory pathway could lead to faster approval and increased availability of biosimilar products.